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FGF2 is a tumor cell survival factor that is exported from cells by an ER/Golgi-independent
secretory pathway. This unconventional mechanism of protein secretion is based on direct
translocation of FGF2 across the plasma membrane. The Na,K-ATPase has previously been
shown to play a role in this process, however, the underlying mechanism has remained
elusive. Here, we define structural elements that are critical for a direct physical interaction
between FGF2 and the α1 subunit of the Na,K-ATPase. In intact cells, corresponding FGF2
mutant forms were impaired regarding both recruitment at the inner plasma membrane
leaflet and secretion. Ouabain, a drug that inhibits both the Na,K-ATPase and FGF2 secretion,
was found to impair the interaction of FGF2 with the Na,K-ATPase in cells. Our findings reveal
the Na,K-ATPase as the initial recruitment factor for FGF2 at the inner plasma membrane
leaflet being required for efficient membrane translocation of FGF2 to cell surfaces.
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In eukaryotic cells, the ER/Golgi-dependent secretory pathwayrepresents the major mechanism of protein transport into theextracellular space1–4. However, additional mechanisms of
protein secretion exist that have collectively been termed ‘uncon-
ventional protein secretion’5,6. A typical example is Fibroblast
Growth Factor 2 (FGF2)7, a cell survival factor involved in tumor-
induced angiogenesis8,9. Following secretion from tumor cells and
their cellular microenvironment, FGF2 exerts its biological func-
tions through both autocrine and paracrine signaling mediated by
the formation of ternary complexes with FGF high-affinity
receptors and heparan sulfates on cell surfaces.
Despite the biological functions FGF2 exerts in the extracellular
space, it lacks a signal peptide required for transport along the
classical, ER/Golgi-dependent secretory pathway5,6,10,11. Based
upon biochemical reconstitution experiments and bulk measure-
ments of FGF2 secretion from cells, unconventional secretion of
FGF2 was found to be mediated by direct translocation of FGF2
across the plasma membrane12–14. This process has recently been
visualized in real time in living cells employing single-molecule
TIRF microscopy12. Unconventional secretion of FGF2 depends
on interactions with the α1 subunit of the Na,K-ATPase15, Tec
kinase16,17, and the phosphoinositide PI(4,5)P217–19 at the inner
plasma membrane leaflet as well as heparan sulfate chains of
proteoglycans at the outer leaflet20,21. Consistently, residues in
FGF2 that mediate interactions with PI(4,5)P2 [K127, R128, and
K133 (refs. 18,22)] and heparan sulfates [K133 (refs. 20,22)] as well
as the residue that is phosphorylated by Tec kinase [Y81
(refs. 16,17)] have been identified and shown to be critical for
efficient secretion of FGF2. In addition, two cysteine residues (C77
and C95) of FGF2 play a critical role in PI(4,5)P2-dependent
formation of membrane-inserted FGF2 oligomers23 that represent
dynamic intermediates of FGF2 membrane translocation5,7. These
findings are in line with the observation that FGF2 retains a fully
folded state during membrane translocation to the cell surface24,25.
Recently, key steps of FGF2 membrane translocation were
reconstituted using giant unilamellar vesicles with all components
being purified to homogeneity22. The findings summarized above
led to a model in which membrane-inserted FGF2 oligomers
serve as intermediates in FGF2 membrane translocation. These are
assembled in a PI(4,5)P2-dependent manner at the inner leaflet
and are disassembled at the outer plasma membrane leaflet
mediated by membrane proximal heparan sulfates10,11. This
model explains directional transport of FGF2 from the cytoplasm
into the extracellular space in an ER/Golgi-independent
manner5,7. The general mechanism of this pathway of uncon-
ventional secretion is also relevant to other unconventionally
secreted proteins5,6. For example, a role for PI(4,5)P2 has been
reported for unconventional secretion of Tau, HIV-Tat, and
Interleukin 1β26–31. In addition, in case of Tau, sulfated glycosa-
minoglycans on cell surfaces have been shown to have a critical
function in trans-cellular spreading that is mediated by uncon-
ventional secretion of Tau from donor cells27,32.
While the core mechanism of FGF2 membrane translocation is
understood in great detail, the role of additional factors in
unconventional secretion of FGF2 remains unclear. In previous
studies, a role for the catalytic α1-subunit of the Na,K-ATPase in
unconventional secretion of FGF2 has been proposed. Initial
evidence was based on the observation that ouabain, an inhibitor
of the Na,K-ATPase, blocks FGF2 transport into the extracellular
space33–35. These findings were corroborated by the observation
that an α1 mutant to which ouabain cannot bind is capable of
restoring FGF2 secretion in the presence of ouabain36. Finally, α1
was one of the strongest hits in a genome-wide RNAi screen for
gene products whose down-regulation inhibits FGF2 secretion
from cells15. Interestingly, α1 has also been suggested to be
involved in unconventional secretion of HIV-Tat37. However, as
opposed to the detailed insight that is available about the core
process of FGF2 membrane translocation, the precise function of
α1 subunit of the Na,K-ATPase in unconventional secretion of
FGF2 is unknown5,7,38,39.
In the current study, we define a sub-domain in the cyto-
plasmic part of α1 that forms the binding surface for FGF2.
Employing a chemical crosslinking approach, we identified a
physical 1:1 complex of FGF2 and this minimal α1 domain as the
main crosslinking product. Using NMR spectroscopy, we iden-
tified two lysine residues (K54 and K60) on the molecular surface
of FGF2 that are involved in binding to α1. Using both docking
studies and molecular dynamics (MD) simulations, we validated
the role of K54 and K60 in a thermodynamically relevant model
system. In this way, we also identified residues in α1 that are
potentially engaged in the protein–protein interaction interface
with FGF2. For one of them (D560), we could establish a direct
role as the interaction with FGF2 was impaired in a D560N
variant form of α1. Similarly, FGF2 variants lacking K54/K60
were found to be largely incapable of binding to α1 as shown by
two different kinds of biochemical protein–protein interaction
assays. These observations were further analyzed in cell-based
secretion assays, demonstrating a drop in FGF2 secretion effi-
ciency when K54 and K60 were replaced by glutamates. Using a
recently established single-molecule TIRF microscopy assay
designed to quantify FGF2 in the vicinity of the plasma mem-
brane in living cells12, we found that K54/60E mutants of FGF2
failed to get efficiently recruited at the inner leaflet of the plasma
membrane. By contrast, a FGF2 variant form lacking the ability to
bind to PI(4,5)P2 was found at the inner leaflet at amounts
comparable to the wild-type protein. These results demonstrate
that FGF2 binding to α1 precedes recruitment of FGF2 by PI(4,5)
P2. Furthermore, as opposed to in vitro experiments demon-
strating efficient binding of FGF2 to PI(4,5)P2 with a KD of about
1 µM17–19,22, these findings suggest that, in the context of intact
cells, α1 is required for efficient binding of FGF2 to PI(4,5)P2.
Finally, we provide conclusive evidence that ouabain inhibits
FGF2 secretion by impairing the interaction of FGF2 with the Na,
K-ATPase at the plasma membrane of cells. We propose that α1
is an auxiliary factor that acts upstream of PI(4,5)P2 to increase
the efficiency of unconventional secretion of FGF2 by accumu-
lating FGF2 at the inner plasma membrane leaflet.
Results
A sub-domain of the α1 subunit that interacts with FGF2. The
starting point of this study was to define a minimal sub-domain
that contains the protein interaction surface for FGF2. The set of
GST-fusion proteins carrying different forms of the cytoplasmic
domain of α1 is shown in Fig. 1a. In addition to this schematic
representation, the corresponding α1 domains are illustrated in a
3D model of full-length α1 (Fig. 1b). They contain either the
complete (GST-α1-CD1-3) or various sub-domains of the cyto-
plasmic domain of α1 as indicated. Based upon a structural
analysis, we identified a globular domain of about 20 kDa in α1
that contains a highly acidic molecular surface as a potential
recruitment site for FGF2. This sub-domain is part of the third
loop of the cytoplasmic domain of α1 (α1-subCD3) that contains
the nucleotide binding site of the α1 subunit of the Na,K-
ATPase34,40. A biochemical pull-down approach was used to
quantify the interaction of FGF2 with the various GST-α1 fusion
proteins (Fig. 1c). The construct containing the complete cyto-
plasmic domain of α1 (α1-CD1-315) was used as a positive con-
trol. These experiments revealed that FGF2 binds with similar
efficiency to α1-CD1-3, α1-CD3 (containing only the third loop
of the cytoplasmic domain of α1), and the small sub-domain of
loop 3 (α1-subCD3). By contrast, FGF2 did bind only weakly to
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both a construct lacking the sub-domain of loop 3 (GST-α1-CD3-
ΔsubCD3) with GST alone used as a negative control (Fig. 1d).
The results from biochemical pull-down experiments were
confirmed employing an AlphaScreen® protein–protein interaction
assay (Fig. 2). Cross-titration experiments using a wide range of
combinations of concentrations of FGF2 and various α1 constructs
demonstrated that FGF2 binds to the complete cytoplasmic
domain (α1-CD1-3), loop 3 alone (α1-CD3) and α1-subCD3, the
Fig. 1 Identification of a sub-domain in the cytoplasmic domain of α1 that is both necessary and sufficient for binding of FGF2. a Schematic
representation of the different GST-tagged α1 constructs used in this study with a comparison to the complete α1 chain of the Na,K-ATPase. Short linkers
were introduced between CD1 and CD2 as well as between CD2 and CD3 as described previously15. A short linker also exists in the α1-CD3Δsub construct
connecting the N- and C-terminal parts of CD3. b Three-dimensional models of the complete α1 chain of the Na,K-ATPase based on the crystal structure of
the Na,K-ATPase from Sus scrofa47 (PDB ID: 3KDP). The different domains were annotated according to topology data from Uniprot (ID P05024,
α1 structure from Sus scrofa). Transmembrane helices are shown in cyan, extracellular domains in yellow, and cytoplasmic CD1 and CD2 domains in shades
of gray. The CD3 part of the cytoplasmic domain is colored in dark pink with the subCD3 region highlighted in red. c Biochemical pull-down experiments of
FGF2 using GST-fusion proteins of various versions of the cytoplasmic domain of α1. Lane 1: FGF2 input (2.5%); lanes 2 and 3: GST control; lanes 4 and 5:
GST-α1-CD1-3; lanes 6 and 7: GST-α1-CD3; lanes 8 and 9: GST-α1-subCD3; lanes 10 and 11: GST-α1-CD3Δsub. Bound (33% of each fraction) and unbound
material (2.5% of each fraction) was analyzed by SDS-PAGE and Coomassie Blue protein staining. The results shown are representative for five
independent experiments. d The intensity of the FGF2 protein bands from SDS-PAGE (panel a) was analyzed with the ImageStudio software package (LI-
COR Biosciences). Ratios of bound versus total FGF2 were calculated and normalized to the amounts of FGF2 bound to GST-α1-CD1-3 containing the
complete cytoplasmic domain of α1. Data are shown as mean ± SD (n= 7). ***p≤ 0.001.
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sub-domain of loop 3 of the cytoplasmic domain (Fig. 2a and
quantified in Fig. 2b). By contrast, FGF2 binding to α1-CD3-
ΔsubCD3 was similar to GST alone which was used as a negative
control (Fig. 2b). Using an untagged version of FGF2 as a
competitor for the interaction of His-tagged FGF2 and GST-tagged
α1 constructs, the AlphaScreen® assay also allowed for a
quantitative comparison of the affinities between FGF2 and α1-
CD1-3, α1-CD3 as well as α1-subCD3, respectively (Fig. 2c15,41). As
reported previously, FGF2 binds to the complete cytoplasmic
domain of α1 with an apparent KD of about 0.8 µM15. With 1.1, 1.3,
and 0.8 µM, similar apparent KD values were found for α1-CD1-3,
α1-CD3 and α1-subCD3, respectively (Fig. 2c). These findings
suggest that the sub-domain of loop 3 in the cytoplasmic domain of
α1 contains the principal binding site for FGF2.
To determine the stoichiometry of the interaction between the
minimal FGF2 binding domain in the cytoplasmic part of α1 (α1-
subCD3) and FGF2, we conducted crosslinking experiments
(Fig. 3). Two types of chemical crosslinkers were chosen targeting
either cysteine (BMOE; Fig. 3a, b) or lysine (DSG; Fig. 3c, d) side
chains. The formation of crosslinking products was monitored by
both a western analysis using anti-FGF2 and anti-α1 antibodies
(Fig. 3a, c) and an SDS-PAGE analysis based upon Coomassie
protein staining (Fig. 3b, d). For both read-outs and crosslinkers,
the main product was characterized by a migration behavior that
is consistent with a molecular weight of about 46 kDa. This
product was recognized by both anti-FGF2 and anti-α1 antibodies
(Fig. 3a, c), suggesting a 1:1 complex of FGF2 and the α1-subCD3.
For BMOE in particular, substantial amounts of the 1:1
crosslinking product were formed as it was readily detectable
by Coomassie protein staining as well (Fig. 3b). Additional
crosslinking products with higher molecular weights were
identified as well which are due to the ability of both FGF2 and
α1 to form homo-oligomers (Fig. 3a–d; lanes 5 and 6). However,
the formation of FGF2/α1 heterodimers occurred preferentially as
they were formed at the expense of FGF2 homodimers (Fig. 3a–d,
lane 7 versus lane 9). These results establish a direct physical
contact between FGF2 and α1 with a heterodimer being the basic
unit of this interaction.
The binding interface between the Na,K-ATPase and FGF2. In
order to map the binding interface of α1-subCD3 on FGF2, NMR
experiments were performed using an FGF2 variant form (FGF2-
C77/95S) that is incapable of oligomerization22,23. 1H-15N-HSQC
spectra of 15N-labeled FGF2-C77/95S in the absence and in the
presence of α1-subCD3 (in molar ratios of 1:1 and 1:2) were
acquired and assignments were transferred from published
data42. Chemical shift differences upon addition of α1-subCD3
were negligible for assigned peaks (<0.04 ppm, Supplementary
Fig. 1) but some signals showed a clear reduction in peak
intensity (Fig. 4, Supplementary Fig. 1). In agreement with the
observed KD value of about 0.8 µM, this suggests a slow to
intermediate exchange regime on the NMR timescale. The larger
size of the complex compared to isolated FGF2 also manifests in a
general line-broadening of signals that is seen as a small but clear
reduction in peak intensities (Supplementary Fig. 1). Three of the
six residues with strong reduction in signal intensities localize to
the region spanning K54 to K60. The two effected lysine residues
K54 and K60 are exposed on the molecular surface of FGF2 and,
Fig. 2 FGF2 binds to α1-subCD3 with sub-micromolar affinity as analyzed by an AlphaScreen protein–protein interaction assay. a Cross-titration
experiments conducted with His-tagged FGF2 and GST-tagged variant forms of the cytoplasmic domain of α1 as indicated. Data were normalized to the
signal intensity measured for His-tagged FGF2-wt and GST-α1-CD1-3. The shown heat map is an average from six biological replicates. See Methods for
details. b Quantification and statistical analysis of the relative alpha signal intensity from the cross-titration experiment with His-tagged FGF2 and the GST-
fusion proteins of the cytoplasmic domain of α1 as indicated in panel a. Data are shown as mean ± SD (n= 6). ***p≤ 0.001. c Determination of affinity
using IC50 values from competition assays. GST-tagged α1 variant forms (CD1-3, CD3, or subCD3) and His-tagged FGF2 proteins were mixed and
subjected to a serial dilution of ΔN25-FGF2 used as an untagged competitor. Data are shown as mean ± SEM (n= 3).
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therefore, were considered to potentially form a charged surface
for the interaction with α1-subCD3.
In a previous study, two cysteine residues on the molecular
surface of FGF2 (C77 and C95) were identified that are absent from
all FGF family members with signal peptides23. These residues were
demonstrated to play a critical role in unconventional secretion of
FGF2 from cells12,22,23. As illustrated in Supplementary Fig. 2,
similar to C77 and C95 (highlighted in yellow), the lysine residues
in position 54 and 60 (highlighted in green) of FGF2 are absent
from most FGF family members traveling through the ER/Golgi-
dependent secretory pathway. By contrast, the majority of residues
such as C33 and C100 are conserved throughout the FGF family
irrespective of the mode of secretion of the respective FGF proteins,
suggesting that they are important for example for the overall fold
of FGF proteins. To test whether K54 and K60 in FGF2 are
residues that are indeed critical for binding to the cytoplasmic
domain of α1, we generated three FGF2 mutants in which these
lysines were substituted by glutamate residues either separately or
combined. In a first series of experiments, these FGF2 mutants
were tested for binding to a GST-fusion protein containing the α1-
subCD3 domain employing biochemical pull-down experiments
(Supplementary Fig. 3). A representative example is given in
Supplementary Fig. 3a with the corresponding quantification and
statistical analysis of four independent experiments shown in
Supplementary Fig. 3b. While both the FGF2-K54E and the FGF2-
K60E mutants already showed reduced binding efficiency, the
interaction of FGF2-K54/60E to α1-subCD3 was strongly impaired.
These results were confirmed using the AlphaScreen® protein–
protein interaction assay (Fig. 5). In panel a, a cross-titration
experiment is shown analyzing a wide range of concentrations
quantifying the interaction between α1-subCD3 and FGF2-wt,
FGF2-K54E, FGF2-K60E as well as FGF2-K54/60E, respectively.
Based on different combinations of concentrations resulting in
the strongest interactions between FGF2-wt and α1-subCD3, a
statistical analysis was conducted (Fig. 5b). Consistent with the
biochemical pull-down experiments (Supplementary Fig. 3),
single amino acid substitutions of either K54 or K60 caused
partial inhibition of FGF2 binding to α1-subCD3. Substitution of
both lysines by glutamates (FGF2-K54/60E) resulted in an almost
complete lack of binding (Fig. 5b).
To test whether substitutions of K54 and K60 in FGF2 cause
pleiotropic effects on other functional properties beyond binding
Fig. 3 The basic binding unit between FGF2 and α1-subCD3 is a heterodimer as analyzed by chemical crosslinking experiments. FGF2 and α1-subCD3
were mixed at a total concentration of 20 µM at molar ratios of 1:1 (+/+), 1:2 (+/++), and 2:1 (++/+) (FGF2/α1–subCD3). As chemical crosslinkers,
bismaleidomethane (BMOE) and disuccinimidyl glutarate (DSG) were used at the molar ratios provided in Methods. Samples were analyzed by SDS-PAGE
followed by either western blotting (a, c) or total protein staining using Coomassie. FGF2 and α1-subCD3 migrate with an apparent molecular weight of 18
and 27 kDa, respectively. The crosslinking product with an apparent stoichiometry of 1:1 shows a migration behavior that corresponds to a molecular weight
of about 45 kDa as indicated. Lane 1: molecular weight standards; lane 2: input FGF2; lane 3: input α1-subCD3; lane 4: FGF2 plus α1-subCD3 without
crosslinker; lane 5: FGF2 plus crosslinker; lane 6: α1-subCD3 plus crosslinker; lanes 7–9: FGF2 plus α1-subCD3 at 1:1, 2:1, and 1:2 stoichiometries in the
presence of crosslinker. a BMOE: immunoblots using anti-FGF2 and anti-α1 primary antibodies. c DSG: immunoblots using anti-FGF2 and anti-α1 primary
antibodies. b BMOE: total protein visualized by Coomassie staining. d DSG: total protein visualized by Coomassie staining.
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Fig. 4 NMR analysis of the interaction between FGF2-C77/95S and α1-subCD3. a Shown are two regions of the overlay of 1H-15N-HSQC spectra of
77 µM 15N-labeled FGF2-C77/95S in the absence (gray) or presence of 70 µM (orange) or 138 µM α1-subCD3 (blue). b Signal-to-noise ratios (SN ratio) for
indicated peaks of the spectra shown in a are plotted here with SN(+70 µM α1-subCD3)/SN(-α1-subCD3) in orange and SN(+138 µM α1-subCD3)/SN
(-α1-subCD3) in blue.
Fig. 5 K54 and K60 are required for efficient binding of FGF2 to α1-subCD3 as analyzed by AlphaScreen protein–protein interaction experiments.
a Cross-titration experiments conducted with various forms of His-tagged FGF2 and GST-tagged α1-subCD3. For each biological replicate, data were
normalized to the signal measured for His-FGF2/GST-α1-CD1-3. As indicated by the color legend, data were represented as a heat map with the highest
signal set to 100% (displayed in red) and the lowest signal set to 0% (displayed in blue). The shown heat map is an average from five biological replicates.
For details, see Methods. b Quantification and statistical analysis of relative alpha signal intensities from the cross-titration experiment shown in panel a.
Data are shown as mean ± SD (n= 5). ***p≤ 0.001.
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to α1-subCD3, we compared all four variant forms of FGF2 (wt,
K54E, K60E, and K54/60E) with regard to their ability to bind to
PI(4,5)P2 and to oligomerize (Supplementary Fig. 4a), to bind to
heparin (Supplementary Fig. 4b) as well as tested for potential
folding defects based upon thermal stability (Supplementary
Fig. 4c). These experiments revealed that the substitution of K54
and K60 by glutamates does not have an impact on the
parameters listed above.
In silico analysis of the FGF2/α1–subCD3 binding interface. To
analyze the protein–protein interface between FGF2 and the
cytoplasmic domain of Na,K-ATPase and to evaluate a potential
role of K54 and K60 as residues in FGF2 that are in direct contact
with α1-subunit, we conducted both in silico molecular docking
studies and atomistic MD simulations (Fig. 6, Supplementary
Movie 1). In a first stage, using protein–protein docking proto-
cols, we scanned possible interaction interfaces between α1-
subCD3 and the region in FGF2 exposing K54 and K60. Intensive
molecular docking simulations were conducted by rotating FGF2
around the α1-subCD3 domain and calculating the correspond-
ing interface scores, i.e. the differences in the energy state between
the FGF2/α1–subCD3 complex versus unbound FGF2 and
unbound α1-subCD3. The docking results were filtered and
clustered based upon the root-mean-square deviation (RMSD) for
FGF2 and the most representative structures of the largest
populated clusters were refined employing MD simulations as
explained in Methods. The ultimate goal of this approach was to
find the most stable FGF2/α1–subCD3 interface and to char-
acterize the network of interactions it involves. In Fig. 6a, the
position of FGF2 relative to the full-length Na,K-ATPase is illu-
strated for the WT1 cluster. The human version of the α1-
subCD3 domain was aligned to the same domain of the full-
length crystal structure of the α1-subunit of the Na,K-ATPase
from Sus scrofa (residues T380–V597; PDB ID: 3KDP). Mem-
brane lipids [phosphatidylcholine and PI(4,5)P2] were added to
visualize the position of FGF2 bound to α1 relative to the inner
leaflet of the plasma membrane. To test the stability of the
interface between FGF2 and α1-subCD3, the central structure
[which represents the structure with the smallest average value for
the root-mean-square deviation (RMSD) compared to all other
structures from the same cluster] of the cluster was simulated in
three replicates for 200 ns. The probabilities of physical contacts
as average contact maps of the FGF2/α1–subCD3 interface reveals
a broad network of interactions stabilizing the interface of the
WT1 system (Fig. 6b). As shown in the contact probability and
interaction energy maps (Fig. 6d, f), the FGF2/α1–subCD3
interface is strongly stabilized by multiple electrostatic interac-
tions between the residues E525–K60, E498–R30, K524–D27,
D529-K74, and D560-K54. The contribution of each residue in
stabilizing the FGF2/α1–subCD3 interface (Fig. 6b, c), calculated
by summing up the contact probabilities for each residue indi-
vidually, indicates that K54 and K60 have a high probability to be
involved in the interaction.
The in silico results shown in Fig. 6 suggest the WT1 structure
to be the most probable protein–protein interaction surface
between FGF2 and α1-subCD3. It depends on K54 and K60 and is
characterized by a large number of electrostatic interactions that
are stable throughout the MD simulation time. Furthermore, MD
simulations comparing FGF2-wt with FGF2-K54/60E provided
direct evidence for the WT1 system being the relevant interface
between FGF2 and α1-subCD3. This is evident from the
observation that, in all MD simulations with FGF2-K54/60E
(for details see Methods) and as opposed to FGF2-wt, FGF2-
K54/60E did either dissociate from or was not able to form a
stable interaction with α1-subCD3 (Supplementary Movie 1). In
additions, MD simulations of a variant form of α1-subCD3
(D560N) showed a reduction in the number of contact sites with
FGF2 of about 70% (Fig. 6e). As shown in Fig. 6g, the D560N
substitution is weakening the electrostatic network and, therefore,
destabilizes the interaction interface between FGF2 and α1-
subCD3. Thus, the molecular docking studies and MD simulations
are consistent with the experimental data shown in Figs. 1–5.
To verify a potential role of D560 as well as other residues
derived from the in silico studies described above, we generated
the corresponding α1-subCD3 variant forms and tested them in
protein–protein interaction assays based on AlphaScreen®
technology (Fig. 7). Concentrations between 8 and 500 nM of
both FGF2-wt and the α1-subCD3 variant forms indicated were
analyzed in cross-titration experiments (Fig. 7a). As described in
Methods, selected based on the strongest interactions between
FGF2-wt and the wild-type form of α1-subCD3, various pairs of
concentrations for both binding partners were used to quantify
and statistically evaluate the interaction of all α1-subCD3 variant
forms with FGF2-wt (Fig. 7b). While α1-subCD3 variants with
substitutions of K524 and E525 did not show a phenotype under
these conditions, the D560N substitution in α1-subCD3 resulted
in a highly significant decrease of the interaction with FGF2
(p value= 0.008) (Fig. 7b). All α1-subCD3 variant forms tested
were characterized by normal thermal stability compared to the
wild-type form of α1-subCD3 (Fig. 7c). These studies demon-
strate D560 to represent, to our knowledge, the first structural
element in the α1 subunit of the Na,K-ATPase that plays a direct
role in the interaction with FGF2.
A role for the Na,K-ATPase in FGF2 recruitment and secre-
tion. Using a single-particle TIRF microscopy approach estab-
lished previously12, we quantified FGF2-GFP recruitment at the
inner plasma membrane leaflet of living cells. For the wild type
and the various mutant forms of FGF2 indicated, both widefield
and TIRF images were taken (Supplementary Fig. 5). While the
widefield images allowed for the analysis of total expression levels
of each of the FGF2-GFP fusion proteins indicated, the TIRF
images were processed for the quantification of individual FGF2-
GFP particles per surface area in the vicinity of the plasma
membrane. In Supplementary Fig. 5a, FGF2-GFP fusion proteins
are shown in which K54 and K60 were substituted for glutamates
and compared with FGF2 wild-type. The results shown in Sup-
plementary Fig. 5a along with those from real-time movies
monitoring FGF2-GFP recruitment (Supplementary Movie 2)
suggested that FGF2-K54/60E is impaired regarding physical
contacts with the inner leaflet of the plasma membrane. A larger
data set for each of the FGF2 mutants shown in Supplementary
Fig. 5a and Supplementary Movie 2 was subjected to quantifica-
tion and a statistical analysis as shown in Fig. 8. The number of
FGF2-GFP particles in the vicinity of the plasma membrane were
normalized to surface area with each data point representing the
analysis of one cell. These experiments demonstrated that sub-
stitution of K54 and K60 by glutamates reduced the number of
FGF2-GFP particles at the inner plasma membrane leaflet by
about 50% (Fig. 8a, c). In additional experiments, the substitution
of K54 and K60 was combined with mutations in the PI(4,5)P2-
binding site of FGF2 (Supplementary Fig. 5b, Fig. 8b, c, Supple-
mentary Movie 3). These experiments revealed that mutations
restricted to the PI(4,5)P2-binding site in FGF2 alone did not
affect FGF2-GFP recruitment at the inner plasma membrane
leaflet (Fig. 8b, c). In addition, the combination of substitutions of
K54/K60 and mutations in the PI(4,5)P2-binding site of FGF2
caused a similar phenotype compared to what was observed for
K54/60E alone (Fig. 8b, c). The differences in the efficiency of
FGF2 recruitment at the inner leaflet between FGF2 variant forms
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defective in either α1 binding (FGF2-K54/60E) or PI(4,5)P2
binding (FGF2-K127Q/R128Q/K133Q) are particularly evident
following GFP background correction (Fig. 8c). While substitu-
tion of K54 and K60 by glutamates reduced FGF2-GFP recruit-
ment by almost 50%, the FGF2 mutant incapable of binding to PI
(4,5)P2 was fully functional with regard to recruitment at the
inner plasma membrane leaflet. In addition, when both sets of
amino acid substitutions were combined, the observed phenotype
was not stronger compared to the K54/60E substitution alone
(Fig. 8c). These findings suggest that, during recruitment at the
inner plasma membrane leaflet, the physical contact of FGF2 with
α1 subunit of the Na,K-ATPase precedes the interaction of FGF2
with PI(4,5)P2. Furthermore, in a cellular context, the data shown
in Supplementary Fig. 5 and in Fig. 8 imply that the interaction of
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FGF2 with α1 facilitates the subsequent binding of FGF2 to PI
(4,5)P2, i.e. α1 acts upstream of PI(4,5)P2.
We further tested whether amino acid substitutions that
impair the interaction of FGF2 with α1 subunit of the Na,K-
ATPase do affect secretion of FGF2-GFP to the cell surface
(Fig. 9). These experiments included FGF2-GFP variant
forms in which K54 and K60 were replaced by glutamates
(Fig. 9a, b) and were also combined with amino acid
substitutions (K127Q/R128Q/K133Q) that compromise the
ability of FGF2 to bind to PI(4,5)P2 (Fig. 9c, d). Following
induction of protein expression with doxycycline, a cell surface
biotinylation assay was used to quantify the extracellular
amounts of the FGF2-GFP fusion proteins indicated20,23,41,43.
These experiments revealed that a K54/60E substitution caused
a significant impairment of FGF2-GFP transport to the cell
surface with only 60% efficiency compared to the wild-type
form of FGF2-GFP (p value ≤ 0.001) (Fig. 9a, b). When K54/
60E and K127Q/R128Q/K133Q substitutions were combined,
the efficiency of FGF2-GFP secretion dropped to less than 20%
compared to the wild-type form of FGF2-GFP (Fig. 9c, d). This
phenotype was similar to a mutant form of FGF2-GFP that
lacks two cysteine residues (C77/95A) required for FGF2
oligomerization and the formation of membrane translocation
intermediates22,23. Our combined findings suggest that efficient
secretion of FGF2-GFP into the extracellular space is facilitated
by a direct interaction of FGF2 with the cytoplasmic domain of
α1 subunit of the Na,K-ATPase, a physical contact that
precedes the interaction of FGF2 with PI(4,5)P2.
Fig. 6 Characterization of the molecular interface between FGF2 and α1-subCD3 based on in silico docking studies and atomistic molecular dynamics
simulations. a Representative structure of the WT1 cluster for in silico docking of FGF2 and α1-subCD3. b Average structure of the FGF2/α1–subCD3
interface. c Critical residues in the FGF2/α1–subCD3 interface including K54 and K60. d Pairwise contact map with all residues for the FGF2/α1–subCD3-
wt interface. e Pairwise contact map with all residues for the FGF2/α1–subCD3-D560N interface. f Pairwise average interaction energy map for the FGF2/
α1–subCD3-wt interface. g Pairwise average interaction energy map for the FGF2/α1–subCD3-D560N interface. In panel a, the most representative
structure of the WT1 cluster is illustrated. The human α1-subCD3 domain was aligned to residues T380–V597 of the crystal structure of the α1-subunit of
the Na,K-ATPase from Sus scrofa (PDB ID: 3KDP). The Na,K-ATPase is represented as an orange surface with the α1-subCD3 domain highlighted using a
darker shade. FGF2 is shown as a violet surface. The PI(4,5)P2 and phosphatidylcholine membrane lipids are represented using van der Waals spheres with
red and gray colors, respectively. In panel b, an average structure of the FGF2/α1–subCD3 interface is shown illustrating the contribution to the interaction
for each residue individually. It is defined as the sum of the probabilities of contacts for each residue and it is represented as a colored surface using the
RGB color scale. Panel c highlights critical residues responsible for the FGF2/α1–subCD3 interaction including the FGF2 residues K54 and K60. Panels
d and e show a pairwise contact map with all residues between FGF2/α1–subCD3-wt and FGF2/α1–subCD3-D560N, respectively. As a threshold, a
probability of contact of more than 50% was set. Panels f and g show the average interaction energy (electrostatic and van der Waals contributions) of
each residue pair between FGF2/α1–subCD3-wt and FGF2/α1–subCD3-D560N, respectively.
Fig. 7 Structural elements in α1-subCD3 with relevance for the binding interface with FGF2. a Cross-titration experiments conducted with His-tagged
FGF2 and variant forms of GST-tagged α1-subCD3. A representative intensity map is shown with a color code for binding efficiency as indicated.
b Quantification and statistical analysis of the relative alpha signal intensities comparing the interaction of His-tagged FGF2 with the variant forms of GST-
tagged α1-subCD3 indicated. Data were normalized based on the signal intensity for FGF2/α1–subCD3. Standard deviations are shown. For details, see
Methods. c Analysis of protein folding measuring thermal stability of α1-subCD3 variant forms. Protein samples of 10 µl at a final concentration of 3 mg/ml
were analyzed by differential scanning fluorimetry (nanoDSF)44. Data are shown as mean ± SD (n= 4). For details, see Methods.
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Ouabain inhibits FGF2 recruitment by the Na,K-ATPase. To
elucidate the mechanism by which ouabain inhibits unconventional
secretion of FGF2, we conducted experiments probing proximity of
the α1 subunit of the Na,K-ATPase and FGF2 in a cellular context15
(Fig. 10). As expected, the vast majority of proximity events
between α1 and FGF2 (red dots in Fig. 10a–c) were found in the
vicinity of the plasma membrane (Fig. 10a, b). Experiments with
increasing concentrations of ouabain between 12 and 50 µM were
conducted against a mock control. As shown in the statistical
analysis depicted in Fig. 10d, ouabain caused a significant decrease
of α1/FGF2 proximity events in a concentration-dependent manner
(p value ≤ 0.001). Since ouabain binds to α1 within its membrane-
spanning domain, it is not capable of being a direct competitor of
FGF2 binding to the subCD3 domain in the cytoplasmic part of α1.
Consistently, we previously demonstrated that ouabain does not
inhibit the interaction between the cytoplasmic domain of α1 and
FGF2 when analyzed with purified components in vitro15. The
results shown in Fig. 10 demonstrate that ouabain binding to the
membrane-spanning region of α1 inhibits recruitment of FGF2
which, in turn, results in efficient secretion of FGF2. These findings
explain the ability of ouabain to impair FGF2 secretion from cells.
Discussion
In the current study, we identified a sub-domain in the cyto-
plasmic part of α1 (α1-subCD3) that mediates a direct physical
interaction with FGF2. The basic unit of this interaction is a
heterodimer with a KD in the sub-micromolar range. The identi-
fication of α1-subCD3 as a minimal binding partner of FGF2 with
about 25 kDa in size allowed for solution NMR experiments. This
led to the identification of two lysine residues in position 54 and
60 on the molecular surface of FGF2 that were found critical for
the interaction with α1-subCD3. Intriguingly, even though FGF
family members in general are highly conserved reflecting the
structural needs for building up the typical FGF fold, K54 and K60
represent FGF2-specific residues that are absent from most FGF
family members carrying signal peptides for ER/Golgi-dependent
protein secretion. Therefore, similar to what has previously
been reported for two cysteine residues on the molecular surface
of FGF2 (ref. 23), the exclusive presence of both K54 and K60
in FGF2 points at a specific function of these residues in uncon-
ventional secretion of FGF2. Using various kinds of
protein–protein interaction assays, we confirmed the NMR results
demonstrating that FGF2 variant forms lacking K54/K60 are
impaired in binding to α1-subCD3. These experiments were fur-
ther validated by in silico docking studies and atomistic MD
simulations demonstrating a role for K54/K60 in FGF2 binding to
α1-subCD3 in a thermodynamically relevant model system. The
use of molecular docking studies and MD simulations also allowed
for identifying structural elements in the α1-subCD3 domain as
components of the α1/FGF2 interface. With an aspartate residue
(D560) in the subCD3 domain of α1, we could experimentally
validate the, to our knowledge, first structural component known
to play a direct role for the interaction between α1 and FGF2.
The biochemical and structural findings described above were
found to be functionally relevant in a cell-based model system
with FGF2 secretion being impaired in the absence of K54/K60.
We made use of a recently established single-particle imaging
Fig. 8 FGF2-GFP recruitment at the inner leaflet depends on direct
interactions with the cytoplasmic domain of α1. a FGF2-wt versus FGF2-
K54/60E (FGF2 mutant deficient in binding to α1). b FGF2-wt versus FGF2-
K54/60E in a K127Q/R128Q/K133Q background (FGF2 mutant deficient in
binding to PI(4,5)P2). c Direct comparison between FGF2-K54/60E and
FGF2-K127Q/R128Q/K133Q following GFP background subtraction.
Quantification of FGF2-GFP membrane recruitment at the inner leaflet of
intact cells for all wild-type and mutant forms of FGF2 shown in panels
a and b of Supplementary Fig. 5. Time-lapse TIRF movies with a total of 100
frames (100ms/frame) were analyzed using the Fiji plugin TrackMate12.
The number of GFP particles were normalized for both surface area and the
relative expression levels of each FGF2 fusion protein in the corresponding
cell line. In panel a, FGF2 mutants defective in binding to α1 are shown
(K54E, K60E, and K54/60E). In panel b, the same mutants were combined
with mutations in the PI(4,5)P2 binding pocket of FGF2 (K127Q/R128Q/
K133Q). The mean values of each condition are shown in brackets with the
wild-type form of FGF2-GFP set to 1. Data are shown as mean ± SD (n= 4).
***p≤ 0.001. In panel c, the most important conditions were directly
compared following GFP background subtraction and are shown as bar
graphs. Data are shown as mean ± SD (n= 6). P value for (a) was 0.0106;
p value for (b) was 0.0115.
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system studying FGF2 membrane recruitment at the inner plasma
membrane leaflet employing real-time TIRF microscopy in living
cells12. Intriguingly, we found that a FGF2 mutant lacking both
K54 and K60 as well as the three critical residues (K127/R128/
K133) of the PI(4,5)P2-binding pocket was indeed impaired in
binding to the inner leaflet. However, when the two sets of
mutations were looked at separately, only the substitution of K54/
K60 by glutamates caused a decrease in FGF2 recruitment at the
inner leaflet. These findings have two important implications with
(i) FGF2 binding to the α1-subunit of the Na,K-ATPase precedes
FGF2 binding to PI(4,5)P2 and (ii) the physical contact of FGF2
at the inner leaflet with α1 facilitates subsequent interactions of
FGF2 with PI(4,5)P2. Thus, beyond the identification of both a
sub-domain in the cytoplasmic part of α1 and residues on the
surface of FGF2 required for a direct interaction between these
proteins, our findings suggest a function of α1 as an auxiliary
factor in unconventional secretion of FGF2 that increases the
efficiency of PI(4,5)P2-dependent FGF2 oligomerization and
membrane translocation. In this context, it is an interesting
observation that, as opposed to in vitro experiments in which
FGF2 can bind to PI(4,5)P2 in the absence of other factors18,19, α1
appears to be important in intact cells to enable efficient binding
of FGF2 to PI(4,5)P2. Thus, the α1-subunit of the Na,K-ATPase
may serve as a factor that accumulates FGF2 at the inner plasma
membrane leaflet, facilitating PI(4,5)P2-dependent FGF2 mem-
brane translocation to the cell surface. Furthermore, it is an
interesting hypothesis for future studies as to whether this
function is linked to a modulation of the activity of the Na,K-
ATPase to maintain a functional Na/K gradient across the plasma
membrane during active events of FGF2 membrane translocation,
a process that may transiently disturb the integrity of the plasma
membrane. Finally, our study also sheds light on the mechanism
by which ouabain inhibits FGF2 secretion. While ouabain does
not affect the interaction of recombinant forms of the cytoplasmic
domain of α1 and FGF2 in vitro15, we found that, in a cellular
context, ouabain inhibits α1/FGF2 proximity events at the plasma
membrane. These findings suggest that, through ouabain binding
to the transmembrane region of α1, conformational changes
occur in the cytoplasmic domain that impair recruitment of
FGF2. With this interaction being important for efficient
Fig. 9 Efficient secretion of FGF2 from cells is facilitated by its interaction with α1-subunit of the Na,K-ATPase. a Cell surface biotinylation experiments
were conducted as described in Methods using stable CHO-K1 cell lines expressing either FGF2-wt-GFP, FGF2-K54E-GFP, FGF2-K60E-GFP, FGF2-K54/
60E-GFP, or FGF2-C77/95A-GFP in a doxycycline-dependent manner. Aliquots from the total cell lysate (1.6%) and from the biotinylated fraction (33.3%;
corresponding to the cell surface population of proteins) were subjected to SDS-PAGE and western blotting. Anti-GFP antibodies were used to detect the
various FGF2-GFP fusion proteins indicated. Anti-GAPDH antibodies were used to detect intracellular GAPDH as a control for cell integrity during cell
surface biotinylation. Primary antibodies were detected by fluorophore-labeled secondary antibodies and quantified using the Odyssey® CLx Imaging
System (LI-COR Biosciences). b The efficiency of FGF2-GFP secretion of each variant form shown in panel a was quantified and normalized to the wild-type
form that was set to 100%. Data are shown as mean ± SD (n= 4). P value for a was 0.0161. ***p≤ 0.001. c Stable CHO-K1 cell lines expressing either
FGF2-wt-GFP, FGF2-K127Q/R128Q/K133Q-GFP, FGF2-K54E/K127Q/R128Q/K133Q-GFP, FGF2-K60E/K127Q/R128Q/K133Q-GFP, FGF2-K54/60E/
K127Q/R128Q/K133Q-GFP, or FGF2-C77/95A-GFP in a doxycycline-dependent manner were analyzed by cell surface biotinylation as described in the
legend to panel a. d The efficiency of secretion of each variant form of FGF2-GFP shown in panel c was quantified and normalized as described in the legend
to panel b. Data are shown as mean ± SD (n= 4). ***p≤ 0.001.
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secretion of FGF2 from cells, our results provide a plausible
explanation of how ouabain inhibits this process.
Recently, beyond the established function of α1 in unconven-
tional secretion of FGF2, evidence has been reported for a similar
role of α1 in the secretion of HIV-Tat from HIV-infected
T cells37. Along with the well-established role for PI(4,5)P2 in
unconventional secretion of HIV-Tat30,31, these findings point at
a shared secretory mechanism between FGF2 and HIV-Tat.
Furthermore, with Tau and Interleukin 1β, two additional
extracellular factors secreted by unconventional means, even
more examples have been reported for unconventional secretory
processes that depend on PI(4,5)P2 as a prerequisite for their
transport into the extracellular space27–29,32. Thus, after decades
of research on unconventional secretory mechanisms in mam-
malian cells, common features between pathways that are taken
by proteins functionally as different as FGF2, Interleukin 1β, Tau,
and HIV-Tat are beginning to emerge.
Methods
Biochemical protein–protein interaction assays. Recombinant proteins were
expressed in E. coli and purified according to standard procedures. The 18 kDa
isoform of FGF2 was expressed and purified as a N-terminally His6-tagged protein.
For competition assays, a non-tagged form of FGF2 lacking 25 residues at the
N-terminus (ΔN25-FGF2) was expressed and purified. For NMR spectroscopy, a
monomeric FGF2 variant form (C77/95S) was expressed in M9 minimal medium
with 15N-NH4Cl as the sole nitrogen source in order to produce FGF2 as a 15N-
labeled protein. In addition, recombinant forms of FGF2 were expressed and
purified in which K54 and K60 were substituted by glutamates as indicated.
Four variant forms of the cytoplasmic domain of α1 were expressed as N-
terminal GST-fusion proteins. This included a fusion of the three main loops of the
cytoplasmic domain [GST-α1-CD1-3 (ref. 15)], the third loop of the cytoplasmic
domain alone [GST-α1-CD3; T339-L772 from human α1)15], a small sub-domain
of loop 3 (GST-α1-subCD3; T382–A598 from human α1), and the third
cytoplasmic loop of α1 lacking the above-mentioned sub-domain of loop 3 (GST-
α1-CD3Δsub; C343-L381 linked to A598-L772 from human α1). As shown in
Figs. 6 and 7, based on MD simulations, several GST-tagged variant forms of
α1-subCD3 were generated carrying amino acid substitutions in the potential
α1/FGF2 interface.
To test the ability of FGF2 variant forms to bind to PI(4,5)P2 concomitant with
oligomerization, FGF2 (10 µM) was incubated with liposomes (2 mM total lipid)
with a plasma-membrane-like lipid composition containing 3 mol% of PI(4,5)P2.
As described previously17,18, experiments were conducted in a final volume of 50 µl
HK buffer (150 mM KCl, 25 mM HEPES, pH 7.4) in an Eppendorf Thermomixer
at 25 °C at 500 rpm. After 4 h of incubation liposomes were sedimented for 10 min
at 16,000g, and washed with 100 µl HK buffer. Pellets were dissolved in 20 µl non-
reducing SDS sample buffer and heated for 10 min at 65 °C. Samples were analyzed
on 1.0 mm NuPAGE 4–12% non-reducing Bis-Tris gels/MES-running buffer
Fig. 10 Ouabain inhibits proximity events between the α1-subunit of the Na,K-ATPase and FGF2 in a cellular context. DuoLink assays (PLA®; Sigma-
Aldrich) were conducted to quantify proximity of the α1 chain with FGF2 in a cellular context as described previously15. Cells were incubated with ouabain
for 2 h at the concentrations indicated. Cells were fixed with acetone. Nuclei were labeled with Sytox green (Life Technologies) and cells were imaged by
confocal microscopy. For further details, see Methods. a Representative example of mock-treated HeLa cells. Scale bar= 10 µm. b Selected area of panel a
at a higher magnification. DuoLink proximity events (red dots) in the vicinity of the plasma membrane are labeled with white arrowheads. c Representative
example for cells treated with 50 µM ouabain. d Quantification, normalization, and statistical analysis of α1/FGF2 proximity events in the absence and
presence of ouabain at the concentrations indicated. Images were analyzed with the DuoLink Image Tool Software (Olink Bioscience). Background signals
were subtracted and data were normalized relative to the mock control. Data are shown as mean ± SD (n= 5). P value for (a) was 0.1124; p value for
(b) was 0.0381. ***p≤ 0.001.
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(Invitrogen) and proteins were stained with Coomassie InstantBlue (Expedeon).
Input lanes contained 50% of FGF2 used in the oligomerization assays.
FGF2 variant forms were further compared to FGF2-wt with regard to their
ability to bind to heparin. Heparin Sepharose 6 Fast Flow (GE Healthcare) beads
(10 µl slurry) were washed four times in phosphate-buffered saline (PBS) and
incubated for 1 h at room temperature with the FGF2 variant forms indicated
(15 µg protein each in a total volume of 200 µl PBS). Following sedimentation of
the beads and extensive washing, binding efficiency was analyzed by SDS-PAGE
and protein staining using Coomassie InstantBlue (Expedeon).
To determine native protein folding by means of thermal stability, the various
FGF2 and α1 variant forms used in this study were analyzed in nanoDSF
experiments using a Prometheus NT 48 instrument (Nanotemper)44. This
procedure monitors the light absorbance of proteins at 330 and 350 nm along a
thermal gradient. The ratio of A330nm/A350nm was plotted as a function of the
temperature. This allows for determining the unfolding transition midpoint, i.e. the
melting temperature of a protein. The FGF2 and α1 variant forms indicated were
used in a volume of 10 µl at a final concentration of 1.5 mg/ml.
Biochemical pull-down experiments. For this set of experiments, Glutathione
Sepharose beads were equilibrated in PBS buffer and incubated with the GST-
tagged variants of α1 as indicated. GST alone was used as a negative control. GST-
coupled Sepharose beads were blocked with 3% (w per v) BSA in PBS supple-
mented with 1 mM Benzamidine and 0.05% (w per v) Tween 20 (buffer A), washed
extensively in buffer A. Finally, beads were resuspended with five bed volumes of
buffer A. Per experimental condition, 75 µl of beads solution were incubated with
15 µg of His-tagged FGF2 in a total volume of 200 µl of buffer A for 1 h at room
temperature. Following collection of beads by low-speed centrifugation and
extensive washing with buffer A, bound protein was eluted with SDS sample buffer.
Both bound (33%) and unbound (2.5%) material was analyzed by SDS-PAGE
followed by protein staining using Coomassie InstantBlue. Gels were scanned using
the Odyssey® CLx Imaging System (LI-COR Biosciences) and band intensities were
quantified using the LI-COR ImageStudio software. For quantification, the ratios
between bound and unbound material were calculated for each experimental
condition as indicated.
AlphaScreen-based protein–protein interaction assays. For cross-titration of a
wide range of concentrations of FGF2 and α1 variants and to determine affinity
between FGF2 and α1 the AlphaScreen® protein–protein interaction assay was used
[Figs. 2, 5 and 7 (ref. 15)]. N-terminally His-tagged FGF2 (wild type or mutants as
indicated) and N-terminally GST-tagged α1 variants were cross-titrated from 500
to 8 nM in PBS supplemented with 0.1% (w per v) BSA and 0.05% (w per v) Tween
20. These experiments were conducted in 384-well plates. After 1 h of incubation,
the proteins were incubated with AlphaScreen Ni-NTA acceptor and AlphaScreen®
Glutathione donor beads, each at a final concentration of 11.25 µg/ml in a total
volume of 15 µl. Following two additional hours of incubation, samples were
measured using an EnVision plate reader (PerkinElmer).
For each biological replicate, data were normalized to the signal measured for
His-FGF2/GST-α1 CD1-3 (Fig. 2) or for His-FGF2 WT/GST-α1-subCD3 (Figs. 5
and 7). As indicated in the supplemental raw data source file, a range of
concentration pairs was used for the quantification and statistical analysis of the
FGF2 and α1 variant forms indicated. Data were represented as a heat map with
the highest signal set to 100% (displayed in red) and a value of 0 set to 0%
(displayed in blue) as indicated by the color legend.
To determine binding affinity between His-FGF2-wt and GST-α1 variants as
indicated, competition experiments were conducted. An untagged and N-
terminally truncated form of FGF2 (ΔN25-FGF2) was used as a competitor which
allowed for the determination of IC50 values. For these analyses, optimal
concentrations of FGF2 (62 nM) and α1 (15 nM) were used based upon the cross-
titration experiments described above. The competitor ΔN25-FGF2 was used in a
concentration range between 22.5 µM and 1.4 nM. The respective pairs of His- and
GST-tagged proteins were mixed with the ΔN25-FGF2 competitor in a final
volume of 10 µl at the concentrations indicated. Addition of Alpha beads and
measurements were done as described above. For each protein pair, the median
signal of three technical replicates was calculated, normalized to the signal of the
buffer lane, and plotted against the concentration of the ΔN25-FGF2 competitor.
For each protein pair tested in competition experiments, the ALPHA signal was
normalized to the median ALPHA signal of the buffer lane. Normalized data from
three biological replicates were eventually plotted against the concentration of the
ΔN25-FGF2 competitor. The competitor concentration promoting half-maximal
inhibition (IC50) of the signal was determined by fitting the experimental data with
a non-linear regression model. Under the experimental conditions described here,
the apparent IC50 value corresponds to the dissociation constant (KD) of the
observed protein–protein interaction.
Crosslinking experiments. The crosslinking experiments shown in Fig. 3 were
performed at 25 °C in 25 µl HK buffer (25 mM Hepes, pH 7.4; 150 mM KCl) at a
final protein concentration of 10 µM. When FGF2 and α1-subCD3 were mixed, the
final protein concentration was 20 µM, irrespective of the ratio between FGF2 and
α1-subCD3 (1:1, 1:2, and 2:1). As chemical crosslinkers, BMOE
(bismaleidomethane) and DSG (disuccinimidyl glutarate) were dissolved in 20 mM
DMSO and further diluted in HK buffer to 0.5 mM (BMOE) and 2 mM (DSG),
respectively. Following preincubation of proteins for 30 min, reactions were started
with the addition of BMOE or DSG yielding crosslinker/protein ratios of 1:1
(BMOE) and 4:1 (DSG). After 30 min, samples were quenched with 10 mM DTT
(BMOE) or 20 mM Tris/HCl pH 7.5 (DSG), mixed with an equal volume of SDS
sample buffer containing β-mercaptoethanol, and incubated for 10 min at 70 °C. Of
each sample, 80% were analyzed on 1.5 mm NuPAGE 4–12% Bis-Tris gels (Invi-
trogen) and stained with Coomassie (InstantBlue, Expedeon). For a western ana-
lysis, 2% of each sample were separated on 1 mm NuPAGE 4–12% Bis-Tris gels.
Blots were analyzed using affinity-purified anti-α1-CD1-3 rabbit antibodies15 and
monoclonal anti-FGF2 antibodies (clone bFM-1, Millipore).
Structural analyses using NMR spectroscopy. NMR spectra were recorded at
300 K on a Bruker Avance III 700MHz spectrometer equipped with a 5 mm triple
resonance cryo-probe. 1H-15N-HSQC spectra were acquired of 77 µM 15N-labeled
FGF2-C77/95S in the absence or presence of 70 µM or 138 µM α1-subCD3 in
25 mM HEPES (pH 7.4), 150 mM KCl, 10% D2O with 108 scans and 1024 data
points in the 1H and 96 data points in the 15N dimension. Spectra were processed
with Topspin3.2 (Bruker, Billerica, USA) and analyzed using CcpNMR Analysis
2.4.2 (ref. 45). Peak assignments were transferred from published data [BMRB entry
4091 (ref. 42)] to nearest neighbors in recorded spectra, if possible, leading to an
assignment of 63% of the non-Proline residues. Chemical shift differences were
calculated using the formula Δδ(1H,15N)= (δ(1H)2+ (0.15*δ(15N))2)1/2. Signal-to-
noise ratios were calculated from peak intensities and average noise levels. Over-
lapping peaks were omitted from the analysis.
Multiple sequence alignment. In order to identify residues that are uniquely
present in FGF2 compared to signal-peptide-containing FGF family members, a
multiple sequence alignment was performed using the EMBL-EBI MUSCLE 3.8
tool46. The protein sequence of isoform 3 of FGF2 (18 kDa form; UniprotKB ID
P09038-2) was aligned with canonical sequences of FGF1 (P05230), FGF3
(P11487), FGF4 (P08620), FGF5 (P12034), FGF6 (P10767), FGF7 (P21781), FGF8
(P55075), FGF9 (P31371), FGF10 (O15520), FGF11 (Q92914), FGF12 (P61328),
FGF13 (Q92913), FGF14 (Q92915), FGF16 (O43320), FGF17 (O60258), FGF18
(O76093), FGF19 (O95750), FGF20 (Q9NP95), FGF21 (Q9NSA1), FGF22
(Q9HCT0) and FGF23 (Q9GZV9). Supplementary Fig. 2 shows the part of the
alignment that covers the residues 32–105 of FGF2.
In silico docking studies. The human sequence of the α1-subCD3 domain
(T382–V599) was modeled based upon the existing crystal structure of the Na,K-
ATPase of Sus scrofa [residues T380–V597, PDB ID: 3KDP47]. The two structures
differ in only six amino acids, which is less than 3% of the total amino acid content.
Point mutations using the CHARMM-GUI web server48 were employed to model the
human sequence of the α1-subCD3 domain. From the crystal structure of the Na,K-
ATPase of Sus scrofa, the S391F, S473A, A497S, R500Q, I521L, and L578I substitu-
tions were carried out to model the human structure of the α1-subCD3 domain.
Protein–protein docking studies were performed using the Rosetta 2018
package49–52. The α1-subCD3 domain was first considered as a spherical unit, and
FGF2 was rotated around this sphere, positioning the surface area of FGF2 that
contains K54 and K60 towards the α1-subCD3 surface. About 120,000 structures were
generated with the Rosetta global docking protocol. About 94% of the structures were
discarded based on low interface scores. All structures without contacts between K54
and K60 of FGF2 and the α1-subCD3 domain were discarded as well. Here, a contact
was defined if the distance between any atoms of K54 or K60 in FGF2 and α1-
subCD3 was less than 6 Å. The remaining structures were aligned to the α1-subCD3
domain of the full-length Sus scrofa crystal structure of Na,K-ATPase. All docked
structures with overlaps of FGF2 and α1-subCD3 domains were also removed. This
filtering procedure resulted in 62 candidates of docked structures for further analysis.
For each of them, the Rosetta local docking protocol was employed to refine the global
docking results. Therefore, for each of the 62 candidates, 500 structures were
generated by randomly perturbing FGF2 by 3 Å translation and 8° rotation before the
start of every individual simulation. These 31,000 structures were subjected to the
same filtering procedure, which reduced the set to 33 structures. These were clustered
based on the RMSD value for FGF2 using the Gromos algorithm53 and a RMSD cut-
off for two structures to be neighbors within 0.6 nm, which in turn resulted in four
most populated clusters C1–C4. In each cluster, the most representative structure (as
the centroid of the structures in a given cluster) was chosen as the basis to represent
the wild-type (WT1–WT4), and the FGF2-α1-subCD3 interfaces of these structures
were then tested and refined employing atomistic MD simulations. The first cluster
(C1) was averaged from eleven structures, while the other three clusters (C2–C4) were
averaged from four structures. These clusters had an averaged room-mean square
deviation (RMSD) of 0.232, 0.146, 0.252, and 0.330 nm, respectively.
Atomistic MD simulations. The screening of the most probable FGF2/α1–subCD3
interaction interface was conducted through an in-depth study of the type of
molecular interactions taking place during the simulation time and their residence
period. The analysis of the MD simulations indicated the simulated WT1 cluster to
represent the most stable FGF2/α1–subCD3 interface showing a broad range of
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interactions together with three ion pairs, E525– K60, E498–R30, and K524–D27.
Furthermore, K54 was found to be important as it stabilized the interaction
between E498 and R30. As opposed to the WT1, the contact analysis for the
WT2 system did not show stable contacts as revealed by MD simulations. In this
case, only one pair of residues (K533–M150) was found with a probability of
contacts higher than 50%. This suggests that the WT2 system is unlikely to be
physiologically relevant. Similarly, the WT3 system appears to be unlikely to
represent a relevant interface between FGF2 and α1-subCD3. While it was found to
be stable based on MD simulations and its contact map showed contact frequencies
of >50%, we did not find K54 and K60 to play a crucial role in stabilizing this
potential protein–protein interaction interface. Despite the fact that the
WT3 structure in the third cluster was characterized by a relatively large interaction
interface, only one ion pair was found to stabilize this interface. In the case of the
WT4 system, K54 and K60 were found to play a pivotal role as well as they made
up about 25% of the whole contact interface between FGF2 and α1-subCD3. In this
case, with E397– K54, E542–K60, E542-K153, and E548–K153, four electrostatic
pairs were found to be involved in stabilizing the interaction between FGF2 and α1-
subCD3. However, the network of molecular interactions in the WT4 system was
not as extended as compared to observations in the WT1 system. In conclusion, the
in silico results suggest the WT1 structure as the most probable protein–protein
interaction surface between FGF2 and α1-subCD3 (Fig. 6).
The atomistic MD simulations were performed using the CHARMM36m54 force
field for lipids and proteins, the CHARMM TIP3P force field for water, and the
standard CHARMM36 force field for ions. The GROMACS 2018.3 simulation
package55 was used in all simulations. For FGF2, we used its truncated structure [PDB
ID: 1BFF56] from residue 26 to 154 in its monomeric form and the modeled version
of human α1-subCD3. The N- and C-terminal groups were modeled as charged
residues. The most representative structures of the four clusters were energy-
minimized in vacuum using the steepest descent algorithm. The systems were first
hydrated and neutralized by an appropriate number of counter-ions, followed by
addition of 150mM potassium chloride to mimic the experimental conditions. All
systems were energy-minimized and an equilibration step was used to keep the
temperature, pressure and the number of particles constant (NpT ensemble). During
this step, proteins were restrained in all dimensions. For the production runs, all
atoms in the region involved in the truncation part of α1-subCD3 to the rest of the
Na,K-ATPase were restrained in all directions with a force constant of 1000 kJ/mol to
avoid the unfolding of the α1-subCD3 domain. A second layer of restraints was
applied to the alpha carbons of the residues in the FGF2/α1–subCD3 interaction
interface and the thoroughly restrained part. No restraints were employed in the
residues involved in the FGF2/α1–subCD3 interaction region. The Nose-Hoover
thermostat57 was used to maintain the temperature at 310 K with a time constant of
1.0 ps. The pressure of 1 atm was kept constant using the Parrinello–Rahman
barostat58 with a time constant set to 5.0 ps and isothermal compressibility to a value
of 4.5 × 10−5 bar−1. The isotropic pressure-coupling scheme was used. For neighbor
searching, we used the Verlet scheme with an update frequency of once every 20 steps.
Electrostatic interactions were calculated using the Particle Mesh Ewald method59.
Periodic boundary conditions were applied in all directions. The simulations were
carried out using an integration time step of 2 fs until they reached 200 ns. All
analyses were done for the last 100 ns of the 200 ns long simulation trajectories (unless
stated otherwise) using standard GROMACS tools and in-house scripts. Finally, using
the wild-type structures (WT1–WT4) as a basis, we constructed variant forms of
FGF2 (K54E and K60E; systems M1–M4) and α1-subCD3 (D560N; system A1) by
using the CHARMM-GUI web server. Each of these nine systems were simulated in
the presence of one molecule of FGF2, one molecule of subCD3 and 42922 molecules
of water for a total of 200 ns. A concentration of 150mM of KCl salt was added to
mimic experimental conditions. The systems were neutralized by an appropriate
number of potassium atoms.
Single-molecule TIRF microscopy. Widefield fluorescence and TIRF images were
acquired using an Olympus IX81 xCellence TIRF microscope equipped with an
Olympus PLAPO ×100/1.45 Oil DIC objective lens and a Hamamatsu ImagEM
Enhanced (C9100-13) camera. GFP fluorescence was excited with an Olympus
488 nm, 100 mW diode laser. Data were recorded and exported in Tagged
Image File Format (TIFF) and analyzed via Fiji60.
For the quantification of FGF2-GFP recruitment at the inner leaflet of the
plasma membrane, cells were seeded in µ-Slide 8 Well Glass Bottom (ibidi) 24 h
before live cell imaging experiments. The quantification of FGF2-GFP particles
recruitment to the plasma membrane was achieved through the analysis of time-
lapse TIRF movies. The frame of each cell was selected by widefield imaging. The
number of FGF2-GFP particles were normalized to the cell surface area (μm2) and
to the expression level of FGF2-GFP. The latter was quantified at the first frame of
each time-lapse TIRF movie (for each analyzed cell) using ImageJ. The total
number of FGF2-GFP particles per cell was quantified employing the Fiji plugin
TrackMate61. Background fluorescence was subtracted in all the representative
images and movies shown.
Quantification of FGF2-GFP secretion from cells. Quantification of FGF2-GFP on
cell surfaces was done as described previously20,23,43. Stable CHO-K1 cell lines
expressing various forms of FGF2-GFP in a doxycycline-dependent manner were
cultured in α-MEMmedium supplemented with 10% FCS, 2mM glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37 °C in the presence of 5% CO2. Cells were
seeded at 0.8 × 105 cells per ml in six-well plates (Corning Costar). Following 24 h of
incubation, 1 μg/ml of doxycycline (Clontech) was added to induce FGF2-GFP
expression. After a further 18 h of incubation, cells were washed twice with PBS
supplemented with 1mM MgCl2 and 0.1mM CaCl2 and incubated with 1mg/ml of a
membrane-impermeable biotinylation reagent (EZ-Link Sulfo-NHS-SS-Biotin, Pierce;
dissolved in 150mM NaCl, 10mM triethanolamine, pH 9.0, 2mM CaCl2) for 30min
at 4 °C. Following one washing step and 20min of incubation with 100mM glycine
(dissolved in PBS supplemented with 1mM MgCl2 and 0.1mM CaCl2) at 4 °C, cells
were washed twice with PBS and lysed at 37 °C with 1% Nonidet P-40 [in 50mM Tris/
HCl, pH 7.5, 62.5mM EDTA pH 8, 0.4% deoxycholate, protease inhibitor mixture
(Roche Applied Science)]. Insoluble material was removed by centrifugation (10min,
18,000 × g, 4 °C). Aliquots from the total cell lysate were taken and the remaining cell
lysate was incubated with streptavidin beads (UltraLink immobilized streptavidin;
Pierce) for 1 h at room temperature. Bound material was eluted with SDS sample
buffer for 10min at 95 °C. Total cell lysate and the biotinylated fraction were analyzed
by western blotting using affinity-purified anti-GFP antibodies (1:500) and mono-
clonal anti-GAPDH antibodies (Lifetech-Ambion; 1:20,000) as primary antibodies and
fluorophore-labeled secondary antibodies (LI-COR anti-mouse and anti-rabbit;
1:10,000). Antigen signals were quantified using the Odyssey® CLx Imaging System
(LI-COR Biosciences).
DuoLink® proximity assays. HeLa cells were cultured, processed and analyzed as
described previously15. HeLa cells were grown on glass bottom culture dishes
(MatTek 35 mm dishes with 10 mm microwell glass bottom). At a confluency of
about 70%, cells were incubated for 2 h with indicated concentrations of ouabain or
with DMSO as a mock control. Cells were then washed three times with PBS, fixed
for 4 min with ice-cold acetone at −20 °C, and blocked with 1% BSA/PBS for
15 min at room temperature. Cells were incubated with the primary antibody
solution (rabbit anti-FGF2 (1:500 (ref. 20)) and mouse anti-α1 (1:200; Abcam
ab7671) diluted in 1% BSA/PBS) for 1 h at room temperature. Cells were incubated
with secondary antibodies conjugated to Duolink® In Situ PLA probes (Sigma-
Aldrich) were diluted 1:5 in 1% BSA/PBS for 1 h at 37 °C. Ligation, amplification of
DNA and its detection were conducted according to the manufacturer’s manual
using the DuoLink® detection reagent red (Sigma-Aldrich). Nuclei were stained
with SYTOX green (1:75,000; Life Technologies) prior to imaging by confocal
microscopy. DuoLink proximity signals obtained per cell were quantified using the
Duolink® Image Tool software (Olink Bioscience).
The statistical analysis was based on five biological replicates each consisting of
two technical replicates. Typically, 12–15 pictures with a total of about 150–300
cells were analyzed per technical replicate and condition. For each biological
replicate, the average DuoLink proximity signals (number of red dots per cell as
exemplified in Fig. 10a–c) of the mock condition was set to 100% and other
experimental conditions were normalized accordingly. As a background control,
experiments were conducted with either anti-FGF2 antibodies only or anti-α1
antibodies only and all data sets were corrected accordingly.
Statistics and reproducibility. This manuscript is accompanied by a file that
contains all raw data from the studies contained in this work.
The statistical analyses were based on a one-way ANOVA test (nsp > 0.05; *p ≤
0.05; **p ≤ 0.01; ***p ≤ 0.001). The exact p values are indicated either directly in
the figure or in the legend, unless p ≤ 0.001. The exact sample size is given in the
legend of each figure. The mean ± standard deviation (SD) is displayed, unless
otherwise stated.
In AlphaScreen competition experiments, the mean and the standard error of
the mean (SEM) are given for each protein pair at the given concentration. The
standard error is not displayed if it is smaller than the corresponding symbol. The
IC50 was determined from three biological replicates.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
A supplementary file (Supplementary Data 1) with all raw data and statistical analyses
contained in this work has been published along with the main publication and is
available online. For all further queries, please contact the corresponding author (Walter
Nickel; walter.nickel@bzh.uni-heidelberg.de)
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